Lung Cancer
Web Exclusives | April 19, 2023
A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.
Web Exclusives | April 19, 2023
A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.
Web Exclusives | March 15, 2023
Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
Web Exclusives | March 15, 2023
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
Web Exclusives | March 15, 2023
Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.
Web Exclusives | March 15, 2023
Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.
Web Exclusives | February 21, 2023
A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.
Web Exclusives | February 21, 2023
A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Web Exclusives | February 21, 2023
Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.